导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.49% | 2281/4773 |
| 近一周 | -1.79% | 2828/5465 |
| 近一月 | -3.30% | 2355/5421 |
| 近一季 | -5.75% | 2170/5231 |
| 近半年 | -0.70% | 1556/4920 |
| 近一年 | 3.62% | 2034/4394 |
| 近两年 | 50.58% | 1473/2954 |
| 近三年 | 33.03% | 970/2253 |
| 成立以来 | 63.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.28% 3105/4961 |
12.68% 2139/5312 |
- - |
- - |
| 2025 | 20.68% 2100/4813 |
-0.91% 2459/3635 |
2.23% 1730/4076 |
18.53% 2288/4524 |
0.50% 1966/4813 |
| 2024 | 17.65% 662/3463 |
3.05% 632/2808 |
-1.26% 1011/3014 |
16.98% 1297/3129 |
-1.15% 1603/3463 |
| 2023 | -8.47% 1018/2656 |
4.34% 975/2280 |
-3.79% 905/2385 |
-2.67% 716/2515 |
-6.33% 1723/2655 |
| 2022 | -21.29% 1025/2207 |
-13.64% 802/1919 |
7.08% 535/2016 |
-13.42% 899/2113 |
-1.70% 1730/2208 |
| 2021 | -0.16% 742/1822 |
-2.77% 700/1255 |
5.05% 827/1330 |
-3.92% 669/1466 |
1.73% 821/1822 |
| 2020 | 41.73% 284/1250 |
-7.87% 577/1028 |
15.78% 475/1067 |
16.60% 144/1164 |
13.95% 319/1184 |
| 2019 | - - |
- - |
-1.45% 304/788 |
1.56% 389/850 |
8.19% 340/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 人保沪深300A VS. 长安沪深300非周期A(740101) |